Analysts Set Vericel Corporation (NASDAQ:VCEL) PT at $60.33

Key Points

• Vericel Corporation has received a consensus recommendation of "Buy" from six brokerages, with an average price target of $60.33 over the next 12 months.
• After recent earnings results, Vericel reported a 20.1% year-over-year revenue increase, with quarterly revenue of $63.24 million surpassing expectations.
• The stock currently trades at $35.36, having a market capitalization of $1.78 billion and a PE ratio of 294.69.

Shares of Vericel Corporation (NASDAQ:VCEL - Get Free Report) have earned a consensus rating of "Buy" from the six brokerages that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $60.3333.

A number of equities analysts have recently weighed in on VCEL shares. Wall Street Zen lowered Vericel from a "hold" rating to a "sell" rating in a research report on Monday, May 12th. Canaccord Genuity Group lowered their target price on Vericel from $61.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday, August 1st. Finally, Stephens reiterated an "overweight" rating and set a $67.00 price target on shares of Vericel in a report on Monday, June 16th.

Institutional Investors Weigh In On Vericel

A number of institutional investors and hedge funds have recently bought and sold shares of VCEL. Captrust Financial Advisors increased its position in shares of Vericel by 3.4% during the 4th quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company's stock valued at $336,000 after purchasing an additional 199 shares during the last quarter. State of Wyoming increased its position in shares of Vericel by 3.8% during the 1st quarter. State of Wyoming now owns 10,428 shares of the biotechnology company's stock valued at $465,000 after purchasing an additional 381 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Vericel by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 45,404 shares of the biotechnology company's stock valued at $1,932,000 after purchasing an additional 382 shares during the last quarter. Maryland State Retirement & Pension System increased its position in shares of Vericel by 2.8% during the 2nd quarter. Maryland State Retirement & Pension System now owns 14,795 shares of the biotechnology company's stock valued at $630,000 after purchasing an additional 408 shares during the last quarter. Finally, Scholtz & Company LLC increased its position in shares of Vericel by 0.9% during the 2nd quarter. Scholtz & Company LLC now owns 50,573 shares of the biotechnology company's stock valued at $2,152,000 after purchasing an additional 454 shares during the last quarter.

Vericel Price Performance

Shares of NASDAQ:VCEL traded up $0.66 during trading on Thursday, reaching $36.45. 828,946 shares of the stock were exchanged, compared to its average volume of 618,676. Vericel has a 1-year low of $33.09 and a 1-year high of $63.00. The stock has a fifty day moving average of $38.74 and a two-hundred day moving average of $42.81. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 303.78 and a beta of 1.27.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.03. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company had revenue of $63.24 million for the quarter, compared to analyst estimates of $64.61 million. During the same period in the prior year, the firm earned ($0.10) earnings per share. Vericel's revenue for the quarter was up 20.1% on a year-over-year basis. Sell-side analysts forecast that Vericel will post 0.14 EPS for the current year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.